The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.

Dr. Barbara Goff on HPV-Related Cancers: How Vaccination and Screening Can Eliminate a Global Health Crisis
By Dr. Barbara A. Goff, MD
HPV-related cancers are largely preventable through vaccination and screening. Dr. Barbara Goff explores global disparities, advances in HPV testing, and strategies to eliminate cervical cancer worldwide.

Dr. Barbara Goff on HPV-Related Cancers: How Vaccination and Screening Can Eliminate a Global Health Crisis
By Dr. Barbara A. Goff, MD
HPV-related cancers are largely preventable through vaccination and screening. Dr. Barbara Goff explores global disparities, advances in HPV testing, and strategies to eliminate cervical cancer worldwide.

Dr. Barbara Goff on HPV-Related Cancers: How Vaccination and Screening Can Eliminate a Global Health Crisis
By Dr. Barbara A. Goff, MD
HPV-related cancers are largely preventable through vaccination and screening. Dr. Barbara Goff explores global disparities, advances in HPV testing, and strategies to eliminate cervical cancer worldwide.

When the Treatment Exists but the Patient Never Gets It: Dispatches from the 2026 Summit on Cancer Health Disparities
By Dr. Aayushi Pareek, MD
A powerful dispatch from SCHD26 explores why cancer disparities persist despite scientific advances—and what must change to ensure equitable access to prevention, diagnosis, and treatment.

When the Treatment Exists but the Patient Never Gets It: Dispatches from the 2026 Summit on Cancer Health Disparities
By Dr. Aayushi Pareek, MD
A powerful dispatch from SCHD26 explores why cancer disparities persist despite scientific advances—and what must change to ensure equitable access to prevention, diagnosis, and treatment.

When the Treatment Exists but the Patient Never Gets It: Dispatches from the 2026 Summit on Cancer Health Disparities
By Dr. Aayushi Pareek, MD
A powerful dispatch from SCHD26 explores why cancer disparities persist despite scientific advances—and what must change to ensure equitable access to prevention, diagnosis, and treatment.

Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.

Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.

Bridging the Access Divide in Relapsed DLBCL: Lessons from James’s Journey
By Dr. Nandita Khera
A case-based look at relapsed diffuse large B-cell lymphoma (DLBCL) highlighting barriers to CAR-T and bispecific antibody access and how care coordination, early referral, and system redesign can improve equitable treatment delivery.

What Is Metastatic Cancer? Understanding When and How Cancer Spreads
By Dr. Chandra Lalita Kakarala
What metastatic cancer means, how cancer spreads through lymph nodes and blood, common sites of metastasis, symptoms, diagnosis, and modern treatment options for stage 4 cancer.

What Is Metastatic Cancer? Understanding When and How Cancer Spreads
By Dr. Chandra Lalita Kakarala
What metastatic cancer means, how cancer spreads through lymph nodes and blood, common sites of metastasis, symptoms, diagnosis, and modern treatment options for stage 4 cancer.

What Is Metastatic Cancer? Understanding When and How Cancer Spreads
By Dr. Chandra Lalita Kakarala
What metastatic cancer means, how cancer spreads through lymph nodes and blood, common sites of metastasis, symptoms, diagnosis, and modern treatment options for stage 4 cancer.

Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.

Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.

Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.

Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.

Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.

Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.

Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.

Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.

Highlights of ASCO Gastrointestinal Cancer Symposium 2026: From Bench to Bedside
By Dr. Meghana Singh
Key clinical trial highlights from ASCO GI 2026, covering practice-changing data in gastric, colorectal, pancreatic, and liver cancers, including HERIZON GEA-01, ILLUSTRO, COMMIT II, and BREAKWATER.

Caution about Ivermectin for Cancer Treatment from an Oncologist
By Dr. Binay Shah
An oncologist cautions against the use of ivermectin for cancer treatment, explaining why preliminary lab studies and online misinformation do not replace evidence-based clinical trials.

Caution about Ivermectin for Cancer Treatment from an Oncologist
By Dr. Binay Shah
An oncologist cautions against the use of ivermectin for cancer treatment, explaining why preliminary lab studies and online misinformation do not replace evidence-based clinical trials.

Caution about Ivermectin for Cancer Treatment from an Oncologist
By Dr. Binay Shah
An oncologist cautions against the use of ivermectin for cancer treatment, explaining why preliminary lab studies and online misinformation do not replace evidence-based clinical trials.

2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.

2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.

2025 Oncology Year in Review: Breakthrough Cancer Treatments and Research
By Aishat Motolani, PhD
A comprehensive 2025 oncology year in review exploring breakthroughs in cancer treatment, AI in oncology, immunotherapy approvals, liquid biopsy debates, mRNA vaccines, and global cancer health equity.

San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.

San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.

San Antonio Breast Cancer Symposium 2025: Oncologist's Review of Key Trial Results and Therapeutic Advances
By Dr. Milana Dolezal
An oncologist’s expert review of pivotal clinical trials and therapeutic advances in early and metastatic breast cancer presented at the San Antonio Breast Cancer Symposium 2025.